Microbotics

ARA Develops Microrobot Control System for Targeted Drug Delivery Research

Retrieved on: 
Wednesday, January 24, 2024
Learning, Patient, Field line, Thought, Physics, Research, Overalls, Biology, Social media, Life, Face, Medicine, Microbotics, Drug discovery, Software, Bacteria, Three-dimensional space, Laboratory, Robotics, Doctor of Philosophy, SMU, Xbox, Human body, Engineering, Pharmacy, ARA

Microrobots developed from this research have the potential to provide targeted lifesaving treatments without the need for invasive surgery.

Key Points: 
  • Microrobots developed from this research have the potential to provide targeted lifesaving treatments without the need for invasive surgery.
  • Specifically, within the field of biomedicine, microrobots could be used to provide alternative treatment options, like minimally invasive surgery and targeted drug delivery.
  • The portable magnetic control system developed by ARA can produce high power and high frequency rotating magnetic fields.
  • ARA has focused on the control and manipulation of microrobots in biofluids, building a robust and portable control system that can be deployed quickly at research labs.

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Friday, December 29, 2023
Sale, Form, Form S-1, Microbotics, IP, Security (finance), Exercise

The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to an effective resale registration statement on Form S-1 (File No.

Key Points: 
  • The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to an effective resale registration statement on Form S-1 (File No.
  • In consideration for the immediate exercise of the preferred investment options for cash, Microbot will issue new unregistered series E preferred investment options to purchase up to 1,685,682 shares of common stock.
  • The gross proceeds to the Company from the exercise of the preferred investment options are expected to be approximately $2.73 million, prior to deducting placement agent fees and offering expenses.
  • Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new series E preferred investment options.

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

Retrieved on: 
Friday, September 8, 2023
Cardiovascular and Interventional Radiological Society of Europe, Miniature, ZEUS robotic surgical system, Clinical trial, Coronavirus Scientific Advisory Board, CIRSE, Doctor of Philosophy, Aix-Marseille University, MDR, Professor, Circulatory system, FIH, FDA, Microbotics

BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.

Key Points: 
  • BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.
  • The abstract is to be presented by Professor of Interventional Radiology Vincent Vidal, M.D.
  • PhD, from the Aix-Marseille University and a Scientific Advisory Board Member of Microbot.
  • The team expressed their positive experiences and satisfaction from using the Company’s Robotic Surgery System.

Microbot Medical Announces the Participation of a Key Opinion Leader in the Endovascular Robotics Space at the Next “Access-Ability Live by MBOT” Webinar Series

Retrieved on: 
Wednesday, December 14, 2022
Coronavirus Scientific Advisory Board (Turkey), Physician, Intellectual property, Robotics, Failure, Security (finance), SAB, Cancer, Maintenance, Moyamoya disease, Consultant, Federal, Web conferencing, Vision Guided Robotic Systems, Windows Live Personalized Experience, Health, Growth, Organization, Research, History, COVID-19, Patient, Q&A, Medical device, Microbotics

HINGHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first fully disposable endovascular robotic system, announced that following the success of the first episode of its newly launched “Access-Ability Live by MBOT,” the next episode which is geared toward all stakeholders interested in the endovascular robotic space, will be held on Wednesday, December 21, 2022 at 1:00pm ET, and hosted by the Company’s Chief Medical Officer, Dr. Eyal Morag.

Key Points: 
  • The “Access-Ability Live by MBOT” webinar series focuses on key topics in the healthcare and endovascular space.
  • Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
  • Certain guests of Access-Ability are members of the Scientific Advisory Board (SAB) of Microbot or paid consultants of Microbot, and have received compensation for their services to Microbot.

Microland Announces Partnership with Dynatrace for Observability as a Service

Retrieved on: 
Tuesday, December 6, 2022
Cloud, OAC, QOS, Automation, Observability, ServiceNow, Partnership, Microbotics, NYSE, Workplace harassment, Quality of service, DT, Network, Nextgen, Investment, Industrial, Senior, Artificial Intelligence for IT Operations, SAN, Data, Mobile phone, Microland, Dynatrace, Computer security

The Dynatrace platform provides AI-powered observability, delivering precise answers and intelligent automation for hybrid and multicloud environments.

Key Points: 
  • The Dynatrace platform provides AI-powered observability, delivering precise answers and intelligent automation for hybrid and multicloud environments.
  • This strategic agreement will leverage mutual synergies to deliver unparalleled observability across full-stack enterprise digital application and infrastructure environments.
  • Microland is committed to delivering observability and hyper-automation capabilities on the ServiceNow Platform that are derived from established Microland IPs, including Intelligeni , Microbots , and SmartInsights .
  • We are thrilled to integrate the Dynatrace platform as a core component in the Microland Observability-as-a-Service strategy.

Microland Announces Partnership with Dynatrace for Observability as a Service

Retrieved on: 
Tuesday, December 6, 2022
Cloud, OAC, QOS, Automation, Observability, ServiceNow, Partnership, Microbotics, NYSE, Workplace harassment, Quality of service, DT, Network, Nextgen, Investment, Industrial, Senior, Artificial Intelligence for IT Operations, SAN, Data, Mobile phone, Microland, Dynatrace, Computer security

The Dynatrace platform provides AI-powered observability, delivering precise answers and intelligent automation for hybrid and multicloud environments.

Key Points: 
  • The Dynatrace platform provides AI-powered observability, delivering precise answers and intelligent automation for hybrid and multicloud environments.
  • This strategic agreement will leverage mutual synergies to deliver unparalleled observability across full-stack enterprise digital application and infrastructure environments.
  • Microland is committed to delivering observability and hyper-automation capabilities on the ServiceNow Platform that are derived from established Microland IPs, including Intelligeni , Microbots , and SmartInsights .
  • We are thrilled to integrate the Dynatrace platform as a core component in the Microland Observability-as-a-Service strategy.

Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe’s Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board

Retrieved on: 
Monday, October 31, 2022
CVIR, U.S. Securities and Exchange Commission, SAB, ESMO, Intellectual property, Cardiovascular and Interventional Radiological Society of Europe, Physician, Robotics, Radiation exposure, MD, Adoption, Research, Journal, Private Securities Litigation Reform Act, Failure, CEO, Circulatory system, Forward-looking statement, Maintenance, Interventional radiology, Patient, SEC, Federal, Cancer, European Society of Radiology, Vision Guided Robotic Systems, Goal, 1, Company, Security (finance), CIRSE, Coronavirus Scientific Advisory Board (Turkey), GLOBE, Oncology, Doctor of Philosophy, Growth, NASDAQ, FDA, Technology, Time-invariant system, COVID-19, KOL, Nasdaq, European Society for Medical Oncology, Medicine, Medical device, Microbotics

HINGHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which is continuing to expand its Key Opinion Leader (KOL) support network, today announced that Thierry Jacques De Baère, MD, PhD, is joining the Company’s Scientific Advisory Board (SAB). Dr. De Baère is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, the largest cancer center in Europe. The Company’s SAB now includes 11 members from the U.S., Europe and Israel, who support the rising momentum for the Company’s LIBERTY® Robotic System.

Key Points: 
  • Dr. De Bare is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, the largest cancer center in Europe.
  • The Companys SAB now includes 11 members from the U.S., Europe and Israel, who support the rising momentum for the Companys LIBERTY Robotic System.
  • Dr. De Bare is a leader in the endovascular space, who realized the potential of the LIBERTY Robotic System after his own personal experience.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Innovations in 3D Safety Radars, Vertical Farming, Miniature Robots, Wearable Sweat Sensors & Cancer Diagnostic Devices 2022: Featuring Foodsteps, Inxpect, Lanzatech & Wallfarm - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Technology, Health Technology, Health, Wearables, Mobile Technology, Inside, Electronics, Intelligence, Biotechnology, 3D, Carbon, Pesticide, Automation, Microbotics, Industry, Health, Raman, TOE, Vertical farming, Radar, Skin cancer, Medical imaging

The "Innovations in 3D Safety Radars, Vertical Farming, Miniature Robots, Wearable Sweat Sensors & Cancer Diagnostic Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Innovations in 3D Safety Radars, Vertical Farming, Miniature Robots, Wearable Sweat Sensors & Cancer Diagnostic Devices" report has been added to ResearchAndMarkets.com's offering.
  • This edition of the Inside R&D TOE features information on the use of intelligent platform enabling real-time monitoring of vital parameters in aeroponic and hydroponic vertical farming systems.
  • The TOE also covers innovations based on the use of 3D radar sensors enhancing worker safety within the manufacturing industry while complying with international standards.
  • The TOE additionally provides insights on the use of remote controlled miniaturized robots for surgeries and electronics manufacturing.

Microland Advances to a Premier Partner in the ServiceNow Partner Program

Retrieved on: 
Wednesday, October 12, 2022
Cloud, SAN, HR, Microbotics, Hospitality, Health care, SAM, Public sector, Service, Workplace harassment, ITSM, Corporate services, Business, Weir Group, ESM, Data, Partnership, Senior, Technology, Industrial, Automation, Solution, ServiceNow, Travel, Nextgen, Security, Public utility, Network, Renewable energy, Computer security, Microland

LONDON, SAN JOSE, Calif. and BENGALURU, India, Oct. 12, 2022 /PRNewswire/ -- Microland, a global digital transformation leader, announced its advancement to Premier Partner in the ServiceNow Partner Program. As a Global Professional and Managed Service Partner, Microland offers a broad range of Business and IT transformation solutions and services on the ServiceNow Platform for its global clients. Microland's transition to Premier Partner validates its achievements in the ServiceNow partner assessment methodology, which identifies the activities, accomplishments, and commitments that demonstrate Microland's level of ServiceNow investment and go-to-market maturity.

Key Points: 
  • LONDON, SAN JOSE, Calif. and BENGALURU, India, Oct. 12, 2022 /PRNewswire/ --Microland, a global digital transformation leader, announced its advancement to Premier Partner in the ServiceNow Partner Program.
  • As a Global Professional and Managed Service Partner, Microland offers a broad range of Business and IT transformation solutions and services on the ServiceNow Platform for its global clients.
  • Microland's transition to Premier Partner validates its achievements in the ServiceNow partner assessment methodology, which identifies the activities, accomplishments, and commitments that demonstrate Microland's level of ServiceNow investment and go-to-market maturity.
  • ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.

Microbot Medical Announce Strategic Addition to Scientific Advisory Board Appointment

Retrieved on: 
Tuesday, October 4, 2022
Maintenance, CIRSE, ARRT, Cancer, Oncology, RSNA, NASDAQ, Interventional radiology, Coronavirus Scientific Advisory Board (Turkey), Physician, SEC, Robotics, ACR, Gastrointestinal disease, Technology, Nasdaq, Research, Private Securities Litigation Reform Act, CEO, SUNY, MD, SIR, Interventional oncology, MD Anderson Cancer Center, ARRS, Internal medicine, Sudarshan K. Aggarwal, Federal, SIO, COVID-19, Failure, Goal, Growth, Vision Guided Robotic Systems, SCS, Section, AUR, U.S. Securities and Exchange Commission, Bernie Madoff, Safety, Journal, Yale school, Security (finance), Patient, Yale School of Medicine, University, Forward-looking statement, Portal vein, Publication, Intellectual property, Pittsburgh, GLOBE, SAB, Medical imaging, Pharmaceutical industry, Radiology, Medicine, Microbotics

HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D.

Key Points: 
  • HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D.
  • Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body.
  • Additional information on risks facing Microbot Medical can be found under the heading Risk Factors in Microbot Medicals periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SECs web site at www.sec.gov.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.